Join our CEO Iris Bincovich on October 26, 10:30am EST, presenting at CANNX conference
Innocan Pharma™ is a specialty pharmaceutical company, developing products that harness the unique properties of Cannabinoids combined with smart delivery formulations.
REVOLUTIONARY INJECTABLE cannabinoids DELIVERY SYSTEM
A unique cannabinoid loaded Liposome Platform Technology (“LPT”) facilitating the targeted controlled administration of cannabinoids into the blood stream.
Highly Experienced Team – developed by a highly experienced R&D team in the Hebrew University, Jerusalem, with significant expertise in liposomal delivery systems through to final stage [medicals / drugs].
Targeted Benefits – the technology can enable increased bioavailability, targeted at a specific organ or body part, with precise time and dosage control.
Positive Results – Initial positive results: (i) loading the liposome with a therapeutic dose of CBD and (ii) controlled release of CBD.
Worldwide Exclusive License – InnoCan holds the worldwide exclusive license to commercialize the research results and products developed from this technology.
Patent Pending – Patent application for the LPT was filed October 7, 2019
Monetization Model – LPT has the potential to become a licensing platform to large pharmaceutical companies for specific indications and/or cannabinoids.
REVOLUTIONARY CELL THERAPY – BASED TECHNOLOGY, LOADED WITH CBD
CBD DELIVERY BY EXOSOMES PATENT APPLICATION FILED APRIL 6, 2020
COVID-19, the Corona Virus, is a new, rapidly growing worldwide threat, mainly affecting the lungs.
Innocan, together with Tel Aviv University Prof. Offen and his team, are developing new, revolutionary Cell Therapy – based technology, loaded with CBD, designed to target Corona Virus infected lung cells and Central Nervous System diseases.
CBD-Loaded Exosomes hold the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells.
This treatment, which is expected to be administrated by inhalation, will be tested on a variety of lung infections focusing on patients infected by the corona Virus.
Exosome are small particles created when stem cells are multiplied. It’s been found that Exosomes may target damaged tissue in the lungs when infected by the Corona virus and repairing damaged cells.
Prof. Offen’s team showed great success using Exosomes as a targeted drug delivery system specifically to damaged cells. Together we are developing a novel and revolutionary treatment for the Corona Virus. This product is planned to act as a “guided missile” to the infected lungs, combining the cell healing properties of the Exosome and the anti-inflammatory properties of CBD.
MEET OUR EXECUTIVE CHAIRMAN
Mr Ron Mayron has extensive experience in the pharmaceutical & medical device arena. His core expertise is in Marketing, Sales & Distribution, Mergers & Acquisitions, Business Development, Global Operations & Supply Chain and Strategic Development.
Ron served as CEO of Teva Israel and VP – Israel and Africa between 2009 and 2013 where he was responsible for entering the infant formula market in a partnership with Groupe Danone SA (Euronext: BN) unit Nutricia.
From 2007 to 2008 he managed the Commercial Affairs of the Teva International Group, which included operations in more than 30 countries.
From 2008 to 2009 he established and managed the new Russia & Regional Markets for Teva, including Russia & CIS countries (ex-USSR), Croatia & ex-Yugoslavia and Middle East & North Africa countries.
Ron was responsible for developing the Teva Israel growth strategy and entering new business activities in healthcare. As a result of his leadership, the company realized an increase in income of more than $650 million in 2013.
MEET OUR TEAM